Form 4: Dyne Therapeutics Chief Scientific Officer Oxana Beskrovnaya Sells Shares to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,136 shares of common stock on June 11, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,136 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on December 10, 2021, and December 9, 2022.
• The shares were sold at a weighted average price of $31.34, with individual transactions ranging from $31.00 to $31.52.
• Following the transaction, Beskrovnaya directly owns 147,511 shares, which includes 125,525 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Upon vesting, taxes are due on the value of the shares, and executives often sell a portion of their shares to cover these obligations.
• This practice is common across various biotech and pharmaceutical companies, including Amgen, Biogen, and Gilead Sciences.

Key Dates